- Home
- FFC vs TSHA Comparison
FFC vs TSHA Comparison
Compare FFC & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFC
- TSHA
- Stock Information
- Founded
- FFC 1983
- TSHA 2019
- Country
- FFC United States
- TSHA United States
- Employees
- FFC N/A
- TSHA N/A
- Industry
- FFC Trusts Except Educational Religious and Charitable
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- FFC Finance
- TSHA Health Care
- Exchange
- FFC Nasdaq
- TSHA Nasdaq
- Market Cap
- FFC 741.9M
- TSHA 728.4M
- IPO Year
- FFC N/A
- TSHA 2020
- Fundamental
- Price
- FFC $16.35
- TSHA $2.32
- Analyst Decision
- FFC
- TSHA Strong Buy
- Analyst Count
- FFC 0
- TSHA 5
- Target Price
- FFC N/A
- TSHA $8.20
- AVG Volume (30 Days)
- FFC 164.1K
- TSHA 3.7M
- Earning Date
- FFC 01-01-0001
- TSHA 08-11-2025
- Dividend Yield
- FFC 6.79%
- TSHA N/A
- EPS Growth
- FFC N/A
- TSHA N/A
- EPS
- FFC N/A
- TSHA N/A
- Revenue
- FFC N/A
- TSHA $7,224,000.00
- Revenue This Year
- FFC N/A
- TSHA N/A
- Revenue Next Year
- FFC N/A
- TSHA N/A
- P/E Ratio
- FFC N/A
- TSHA N/A
- Revenue Growth
- FFC N/A
- TSHA N/A
- 52 Week Low
- FFC $11.90
- TSHA $1.05
- 52 Week High
- FFC $14.96
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- FFC 71.60
- TSHA 41.03
- Support Level
- FFC $15.84
- TSHA $2.29
- Resistance Level
- FFC $16.14
- TSHA $2.48
- Average True Range (ATR)
- FFC 0.12
- TSHA 0.17
- MACD
- FFC 0.02
- TSHA -0.05
- Stochastic Oscillator
- FFC 100.00
- TSHA 9.21
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.